160 related articles for article (PubMed ID: 35414476)
1. 'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy.
Davis JA; Youngberg H; Gaffney K; Duco M; Hashmi H
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e680-e684. PubMed ID: 35414476
[TBL] [Abstract][Full Text] [Related]
2. A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.
Stakiw J; Kodad S; LeBlanc R; Sebag M; Hay AE; Kukreti V; Côté J; Camacho F; Fu M; Gul E; Reece D
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):484-490. PubMed ID: 37127473
[TBL] [Abstract][Full Text] [Related]
3. Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.
Hamadeh IS; Moore DC; Martin A; Karabinos A; Hill H; Ndiaye A; Robinson JD; Paul BA; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):470-475. PubMed ID: 33785299
[TBL] [Abstract][Full Text] [Related]
4. Retrospective review of accelerated daratumumab administration.
Patel A; Clark S; Espiritu J; Dechen T; Tran Q
J Oncol Pharm Pract; 2022 Jun; 28(4):816-821. PubMed ID: 33866892
[TBL] [Abstract][Full Text] [Related]
5. Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro-costing analysis in three Italian hematology centers.
Pradelli L; Massaia M; Todisco E; Gherlinzoni F; Furlan A; La Targia M; Grande E; Tripoli IE; Occhipinti F; Comello F; Iannello F; Bellucci S
Cancer Med; 2023 Dec; 12(23):21480-21489. PubMed ID: 37942566
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
Kim K; Phelps MA
Clin Pharmacokinet; 2023 Jun; 62(6):789-806. PubMed ID: 37129750
[TBL] [Abstract][Full Text] [Related]
7. Safety of ninety-minute daratumumab infusion.
Lombardi J; Boulin M; Devaux M; Cransac A; Pistre P; Pernot C; Payssot A; Lafon I; Caillot D; Gueneau P
J Oncol Pharm Pract; 2021 Jul; 27(5):1080-1085. PubMed ID: 32865161
[TBL] [Abstract][Full Text] [Related]
8. Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers.
Soefje SA; Carpenter C; Carlson K; Awasthi S; Lin TS; Kaila S; Tarjan D; Kayal N; Kirkup C; Wagner TE; Gray KS; Kumar S
JCO Oncol Pract; 2023 Apr; 19(4):e542-e549. PubMed ID: 36758192
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab infusion reaction rates pre- and post-addition of montelukast to pre-medications.
Coffman K; Carstens C; Fajardo S
J Oncol Pharm Pract; 2023 Mar; 29(2):333-337. PubMed ID: 35018845
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
Sanchez L; Richter J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richard S; Tam L; Verina D; Chari A
Ther Adv Hematol; 2021; 12():2040620720987075. PubMed ID: 33613930
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
San-Miguel J; Usmani SZ; Mateos MV; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Liu K; Hellemans P; Masterson T; Clemens PL; Luo M; Farnsworth A; Nahi H; Chari A
Haematologica; 2021 Jun; 106(6):1725-1732. PubMed ID: 32354874
[TBL] [Abstract][Full Text] [Related]
12. Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience.
De Novellis D; Fontana R; Palmieri S; Della Pepa R; Di Perna M; Cetani G; Esposito D; Amendola A; Delle Cave G; Serio B; Morini D; Rizzo M; Mettivier L; Trastulli F; Rocco S; Pagano A; Barbato S; Leone A; La Magna M; Bianco R; Rascato G; Carobene A; Cuffa B; Iannalfo M; Giudice V; Svanera G; Annunziata M; Pizzuti M; Frigeri F; Califano C; Ferrara F; Pane F; Selleri C
Target Oncol; 2023 Nov; 18(6):885-892. PubMed ID: 37747623
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
[TBL] [Abstract][Full Text] [Related]
14. Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma.
Bonello F; Rocchi S; Barilà G; Sandrone M; Talarico M; Zamagni E; Scaldaferri M; Vedovato S; Bertiond C; Pavan L; Bringhen S; Cattel F; Zambello R; Cavo M; Mina R
Front Oncol; 2022; 12():851864. PubMed ID: 35359355
[TBL] [Abstract][Full Text] [Related]
15. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting.
Geirnaert M; Howarth J; Martin K; Ricard C; Streilein S; Wasney D; Dao V; Kotb R; Rimmer E; Minuk L
J Oncol Pharm Pract; 2021 Jun; 27(4):907-910. PubMed ID: 33108988
[TBL] [Abstract][Full Text] [Related]
16. Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol.
Hamadeh IS; Reese ES; Arnall JR; Kachur E; Martin AL; Schneider M; Friend R; Paul B; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):526-532.e1. PubMed ID: 32279951
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma.
Shibayama H; Matsumoto M; Kosugi H; Shibayama K; Yamazaki H; Iida S
Int J Hematol; 2021 Jan; 113(1):112-121. PubMed ID: 32915384
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
19. Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab.
Vazirnia D; Del Rio Verduzco A; Soefje SA; Sanders KA; Sandahl TB
JCO Oncol Pract; 2024 Feb; ():OP2300470. PubMed ID: 38408288
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis.
Hughes MS; Lentzsch S
Ther Clin Risk Manag; 2023; 19():1063-1074. PubMed ID: 38164204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
